Neurocrine (NBIX) Q2 Revenue Jumps 17%
Neurocrine Biosciences (NASDAQ:NBIX), a neuroscience-focused biopharma company, delivered a standout earnings report for the second quarter of fiscal 2025, released on July 30, 2025. The report revealed substantial outperformance: Non-GAAP diluted earnings per share reached $1.65, topping analyst expectations of $0.96 (Non-GAAP). GAAP revenue came in at $687.5 million, ahead of the $653.9 million GAAP estimate. The quarter was marked by strong demand for INGREZZA, a launch surge for CRENESSITY, and noticeable increases in research and development investment. Compared to consensus estimates and the prior-year period, both top and bottom-line results delivered significant positive surprises, reflecting robust business momentum despite emerging operational and pipeline risks.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Neurocrine Biosciences specializes in discovering, developing, and commercializing pharmaceuticals aimed at treating neurological and endocrine diseases. Its main revenue driver is INGREZZA, a vesicular monoamine transporter 2 (VMAT2) inhibitor prescribed primarily for tardive dyskinesia, a movement disorder, and for chorea associated with Huntington’s disease. The business also now features CRENESSITY, a new therapy for congenital adrenal hyperplasia (CAH), strengthening its commercial portfolio.
Source Fool.com
Neurocrine Bioscience Aktie
Die Neurocrine Bioscience Aktie in der Gunst der Community: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Kursziel von 144 € für Neurocrine Bioscience weist auf eine potenzielle Steigerung von über 20% gegenüber dem aktuellen Kurs von 106.8 € hin.
